bempegaldesleukin (NKTR-214)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for bempegaldesleukin (NKTR-214), covering 2023-03-28 to 2023-04-11. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) [Phase 3]